Loading clinical trials...
Loading clinical trials...
A Multicenter, Open Study to Assess the Antitumor Effect and Safety of Oral Fludarabine Phosphate (Fludara (SH T 586): 40 mg/m2/Day) Administered in 3 - 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by a Observation Period of 23 Days) in Patients With Indolent Lymphoma
Conditions
Interventions
Fludarabine Phosphate (Fludara)
Locations
17
Japan
Nagoya, Aichi-ken, Japan
Nagoya, Aichi-ken, Japan
Kashiwa-shi, Chiba, Japan
Fukuoka, Fukuoka, Japan
Fukuoka, Fukuoka, Japan
Sapporo, Hokkaido, Japan
Start Date
February 1, 2003
Primary Completion Date
August 1, 2004
Completion Date
August 1, 2004
Last Updated
December 4, 2013
NCT06263491
NCT05529069
NCT05139017
NCT07388563
NCT06337318
NCT07350863
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions